XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.16

-3.2%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (16433)	11/15/2003 6:57:06 PM
From: Cacaito	Read Replies (2) of 17367

Macugen news from Pfixer/Eyetech, what is BpEye status!!! Macugen, a drug being developed by Pfizer Inc. (NYSE:PFE - News) and Eyetech Pharmaceuticals Inc., was 27 percent more effective than placebo at limiting vision loss in patients with the "wet" form of macular degeneration in a late-stage trial. Qlti's Vysudine works only in 30% of subjects (barely works) Lilly's drug is aim more to retina edematous lesions. Dna is the most promising, in paper, pending phase III completion in 2005. But the best is BpEye (my opinion), but nothing in the clinics (aka humans)yet. My posts do not get to the club, I think cause I changed my e-mail address.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next